Drug intelligence / Profile preview

PR600

Development stage: Preclinical
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

**PR600** is an investigational monoclonal antibody targeting a member of the TNF superfamily, with a key role in modulating the function of memory T cells and T follicular helper cells in immune-mediated diseases. Developed using Prometheus Biosciences' proprietary Prometheus360™ platform, it is paired with a proprietary companion diagnostic to identify patients with specific biomarkers likely to experience enhanced clinical responses. The program is designed for precision medicine applications, particularly in inflammatory bowel disease (IBD).[3][9]

Targets

TNFSF8 (CD30 ligand)

Beyond the preview

Go deeper on PR600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR600.

Explore the full profile